Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

Fri, 24th Apr 2020 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - LOSERS

----------

Meggit, down 6.1%. Societe Generale cut the the aerospace and defence contractor to Sell from Hold. On Thursday, Meggitt said it booked a single-digit revenue rise in its first quarter, though it has begun to see a "softening" in trading in its civil aerospace division. The company announced cost cuts of as much as GBP450 million, including salary and job cuts. Meggitt said that to mitigate the likely slump in demand, it will use furlough schemes. It has also taken the "difficult decision" to cut 15% of its workforce.

----------

Rolls-Royce, down 3.2%. Societe Generale cut the jet engine-maker to Sell from Hold.

----------

Whitbread, down 2.8%. The Premier Inn-owner will delay the announcement of its full-year results to ensure the company and its auditors have "adequate time" to complete standard procedures. This also comes following recent joint regulatory guidance in the UK from the Financial Conduct Authority, the Financial Reporting Council and the Prudential Regulation Authority. As previously communicated, it said, Whitbread's performance for the financial year ended February 27 is expected to be in-line with forecasts.

----------

Pearson, down 2.6%. The publishing company's trading in the first quarter was in line with its revised expectations, with revenue falling 5% year-on-year in the period. The company blamed Covid-19 pandemic for the decline in revenue, and warned that if social distancing is prolonged significantly, its North American and International Courseware businesses will see a "more pronounced effect" as campuses and schools remain closed for longer. In the quarter to March-end, Global Assessment revenue declined 3%, International revenue by 10%, and North American Courseware revenue by 10%. The lone bright spot was Global Online Learning, where revenue grew 6%. At the end of the quarter, Pearson had "significant" financial headroom, with immediately available liquidity of about GBP800 million. Its recently completed simplification programme has also identified GBP50 million in cost savings to be realised in 2021. Pearson had previously proposed a final dividend for 2019 of 13.5p, which shareholders will vote on at Friday's annual general meeting.

----------

Burberry, down 2.3%. The luxury fashion designer said it is manufacturing non-surgical gowns at its trench coat factory in Yorkshire and the board will be taking a pay cut. Burberry said its trench coat factory in Castleford is now manufacturing non-surgical gowns and supplying them to the NHS, and the firm has donated more than 100,000 pieces of personal protective equipment so far to help the fight against Covid-19. While Burberry said it continues to have "look hard" at its cost base, reducing non-essential spend, it will continue to maintain base pay for all employees unable to fulfil their roles due to store closures. It will not rely on government support for jobs in the UK, where more than a third of its employees are based.

----------

Legal & General, down 2.0%. The life insurance and financial service firm was down despite its business performing robustly, as it plans a new debt issue to take advantage of "favourable debt market conditions". LGRI, its institutional retirement business, transacted GBP1.2 billion of global pension risk transfer across 12 transactions in the three months to March 31. LGRR, the retail retirement business, delivered individual annuity sales of GBP233.1 million in the quarter, up 4% on a year ago, and lifetime mortgage advances of GBP206.8 million, down 8%. The investment management arm achieved external net flows of GBP10.6 billion and total assets under management are estimated at GBP1.14 trillion. The insurance business achieved total gross written premiums of GBP697.2 million, up 4% on a year ago. Legal & General said its balance sheet remains strong and its solvency ratio "robust". L&G also said it expects to launch a pound-denominated benchmark for tier 2 subordinated debt issuance.

----------

FTSE 250 - WINNERS

----------

FirstGroup, up 3.8%. The transport operator said it has raised GBP300 million under the UK government's Covid Corporate Financing Facility, bolstering the company's committed lending headroom and free cash to GBP800 million. FirstGroup also said its US coach unit Greyhound is expected to be a major recipient of the USD326 million in CARES Act funding allocated to US states in support of intercity bus services. Greyhound's revenue has fallen by 80% since the start of the coronavirus outbreak, and the business is operating just over a third of its pre-outbreak timetabled mileage at present. In the UK, the company's First Bus is operating at 40% normal capacity. It has seen a 90% drop in passenger volumes but is providing services for key workers. The First Rail franchises are operating under the Emergency Measures Agreements, under which the government has waived each operator's revenue. FirstGroup has continued to take proactive steps to prioritise cash flow, it said. A substantial proportion of its total workforce in North America and the UK has been placed on furlough, and the company also has made significant reductions in all non-essential operating and capital expenditures.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Scancell Holdings, up 53%. The cancer immunotherapy treatment firm said it has created a research programme to develop a vaccine for Covid-19. The project will be led by Lindy Durrant, chief scientific officer & professor of Cancer Immunotherapy at the University of Nottingham. Scancell's DNA vaccines target dendritic cells to stimulate high avidity T cells that survey and destroy diseased cells. Scancell's DNA vaccine will target the SARS-CoV-2 nucleocapsid protein and the key receptor-binding domain of the spike protein to generate both T cell responses and virus neutralising antibodies against the SARS-CoV-2 virus. SARS-CoV-2 is the virus that causes Covid-19.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
26 Mar 2024 14:00

Scancell doses first patient in melanoma-focused trials

(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic.

Read more
5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
30 Jan 2024 13:56

Scancell interim loss narrows amid finance gain on derivative

(Alliance News) - Scancell Holdings PLC on Tuesday reported a narrowed loss as it gained on the revaluation of derivative liability.

Read more
17 Jan 2024 14:26

IN BRIEF: Scancell approved by MHRA to add new cohort to Scope trial

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease said - Receives approval from UK's Medicines & Healthcare products Regulatory agency to add a third cohort to the Scope trial. Says the cohort will consist of 43 melanoma patients who will receive iSCIB1+ with doublet therapy, consisting of ipilimumab, under the brand name Yervoy, plus nivolumab, under the name Opdivo. "Exceptional" results from the first 13 patients receiving SCIB1 in the ongoing Scope trial, with an objective response rate of 85%, indicate a high probability of success in this cohort, which is expected to complete in the second quarter of 2024. Meanwhile, recruitment into the iSCIB1+ cohort is expected to be complete by the end of the second quarter as well, with early data expected in the third quarter of 2024.

Read more
19 Dec 2023 13:35

Scancell raises GBP12 million in total from fundraise

(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of shares.

Read more
1 Dec 2023 09:54

IN BRIEF: Scancell raises GBP10.7 million in upsized share sale

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease - Raises GBP10.7 million from the placing and subscription of 97.0 million new shares at 11 pence each. The placing is run by Stifel Nicolaus Europe Ltd and WG Partners LLP. Scancell also plans an open offer of shares at the same price to raise up to another GBP2.0 million. Scancell says the placing was oversubscribed and upsized as a result. After the London market close on Thursday, Scancell had announced plans to raise just GBP6 million in the placing. It says the raise was led by "new institutional and life science specialist investors".

Read more
30 Nov 2023 21:10

EARNINGS AND TRADING: Dispensa and SkinBioTherapeutics losses widen

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
28 Nov 2023 14:57

TRADING UPDATES: Scancell trial progresses; OptiBiotix inks new deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Nov 2023 15:53

UK shareholder meetings calendar - next 7 days

Thursday 23 November 
abrdn UK Smaller Companies Growth Trust PLCAGM
Avation PLCAGM
Bradda Head Lithium LtdAGM
DX Group PLCAGM
Europa Oil & Gas Holdings PLCAGM
Fiske PLCAGM
JPMorgan UK Smaller Cos Investment Trust PLCAGM
Hotel Chocolat Group PLCAGM
Pacific Horizon Investment Trust PLCAGM
Pan African Resources PLCAGM
PZ Cussons PLCAGM
Rosslyn Data Technologies PLCAGM
Friday 24 November 
Base Resources LtdAGM
Cloudbreak Discovery PLCAGM
Esken LtdEGM re Esken Renewables disposal
Neometals LtdAGM
Sovereign Metals LtdAGM
Sylvania Platinum LtdAGM
Monday 27 November 
Chelverton Growth Trust PLCGM re voluntary liquidation
European Smaller Cos Trust PLCAGM
JPMorgan Global Emerging Markets Income Trust PLCAGM
Quadrise PLCAGM
Tribal Group PLCGM re cash offer by Tiger Bidco 1 Ltd
Tuesday 28 November 
Bluefield Solar Income Fund LtdAGM
London Finance & Investment Group PLCAGM
Nanoco Group PLCAGM
Oakley Capital Investments LtdAGM
Wednesday 29 November 
Artemis Resources LtdAGM
Aura Energy LtdAGM
Contango Holdings PLCAGM
CVS Group PLCAGM
Fidelity Asian Values PLCAGM
Ikigai Ventures LtdAGM
Panthera Resources PLCAGM
Reconstruction Capital II LtdAGM
Renishaw PLCAGM
RiverFort Global Opportunities PLCAGM
Sabien Technology Group PLCAGM
Scancell Holdings PLCAGM
Seeing Machines LtdAGM
SLF Realisation Fund LtdAGM
Target Healthcare REIT PLCAGM
Thor Energy PLCAGM
Transense Technologies PLCAGM
Vast Resources PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
10 Nov 2023 11:14

IN BRIEF: Scancell shares up as presents "trailblazing" trial data

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Presents data from first stage of Phase 2 Scope trial at 20th International Congress of the Society for Melanoma Research on Thursday. Trial investigates Scancell's SCIB1 vaccination combined with checkpoint inhibitors in advanced melanoma. Company reported mid-September that SCIB1 combined with CPIs showed an 82% objective response rate. Scope trial is currently in its second stage. Scancell says on Friday that in Cohort 1 nine responses were achieved earlier than expected, and probability of second-stage success is around 90% based on current data.

Read more
31 Oct 2023 14:45

EARNINGS: Frontier IP chair to step down; "busy" Rosslyn narrows loss

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
20 Oct 2023 09:00

IN BRIEF: Scancell says needs more time to publish annual results

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says auditor request additional time to complete standard audit of its results of financial year 2023 that ended on April 30. Cites unforeseen circumstances impacting the audit engagement team. Says audit is substantially complete without any material audit issues.

Read more
17 Oct 2023 15:43

UK earnings, trading statements calendar - next 7 days

Wednesday 18 October 
888 Holdings PLCTrading Statement
Antofagasta PLCTrading Statement
BHP Group LtdTrading Statement
Cirata PLCTrading Statement
Hochschild Mining PLCTrading Statement
Liontrust Asset Management PLCTrading Statement
Quilter PLCTrading Statement
Segro PLCTrading Statement
Sosandar PLCTrading Statement
Whitbread PLCHalf Year Results
Thursday 19 October 
AJ Bell PLCTrading Statement
Centamin PLCQ3 Results
Deliveroo PLCTrading Statement
Dunelm Group PLCTrading Statement
GB Group PLCTrading Statement
Gear4Music PLCHalf Year Results
Hargreaves Lansdown PLCTrading Statement
London Stock Exchange Group PLCTrading Statement
Man Group PLCTrading Statement
Mondi PLCTrading Statement
PensionBee Group PLCTrading Statement
Rathbones Group PLCTrading Statement
Relx PLCTrading Statement
Rentokil Initial PLCQ3 Results
Sabre Insurance Group PLCTrading Statement
Schroders PLCTrading Statement
St James's Place PLCTrading Statement
Friday 20 October 
Foxtons Group PLCTrading Statement
InterContinental Hotels Group PLCTrading Statement
Record PLCTrading Statement
Monday 23 October 
Shanta Gold LtdTrading Statement
South32 LtdTrading Statement
Tuesday 24 October 
Angling Direct PLCHalf Year Results
Anglo American PLCTrading Statement
Barclays PLCQ3 Results
Bunzl PLCTrading Statement
FD Technologies PLCHalf Year Results
Gattaca PLCFull Year Results
Petra Diamonds LtdQ1 Results
Scancell Holdings PLCFull Year Results
Softcat PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
WAG Payment Solutions PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 Sep 2023 13:05

IN BRIEF: Oxford Technology 2 VCT asset value hurt by AIM share falls

Oxford Technology 2 VCT PLC - venture capital trust investing in quoted and unquoted technology companies - Net asset value of OT1 shares falls by 16% to 37.9 pence on August 31 from 45.3p on February 28. Similarly, NAV of OT2 shares falls to 20.5p from 25.1p, of OT3 shares to 23.6p from 33.7p, and of OT4 shares to 25.4p from 29.7p. No dividends are paid during the half year, nor are any shares bought back.

Read more
19 Sep 2023 14:32

Scancell celebrates "positive" clinical trial data for cancer vaccine

(Alliance News) - Scancell Holdings PLC shares surged on Tuesday after the company announced positive results from the phase 2 clinical trial of its SCIB1 treatment for advanced melanoma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.